ARLINGTON, Va., March 10 /PRNewswire/ -- BioInformatics, LLC announces availability of its newest report, Prospering in a Down Market: Strategies for Life Science Suppliers. In this report, BioInformatics, LLC (www.gene2drug.com), the premier research and advisory firm serving the life science market, provides hard data and analysis that supports fast -- and strategic -- decision-making for life science suppliers. BioInformatics, LLC fielded a detailed 45-question survey to more than 500 senior scientists and lab managers working in universities, pharmaceutical and biotechnology companies.
The report is available at pre-release pricing for the remainder of this week, until March 15, 2009. This special pricing is at a significant reduction off the regular pricing which will take effect next Monday, March 16, 2009.
Providing a roadmap for the life science supplier, this study compares and contrasts FY2008 (actual) and FY2009 (projected) lab budgets, revealing anticipated trends and changes. 14 product categories are examined using multiple variables, including current suppliers and projected expenditures through FY2010. The following companies were chosen most frequently as the primary supplier in at least one of the product categories:
Affymetrix (Nasdaq: AFFX) BD BioSciences (NYSE: BDX) Bio-Rad Laboratories (NYSE: BIO) Dell Computer Corp (Nasdaq: DELL) Carl Zeiss Life Technologies (Nasdaq: LIFE) PerkinElmer (NYSE: PKI) Qiagen (Nasdaq: QGEN) Thermo Fisher Scientific (NYSE: TMO)
Life science suppliers plan to use this study to forecast economic trends to Boards of Directors, analysts and investors, and pinpoint areas of growth, stability and decline by market segment, region and product category. Scientists surveyed expressed their opinions as to how vendors can tailor marketing programs to enhance customer loyalty, and at what percentage price decrease they'd be willing to switch to lower cost suppliers. Ultimately, Prospering in a Down Market: Strategies for Life Science Suppliers will inform strategies in R&D, Product Development and Marketing/Sales.
"Nearly half of respondents surveyed said they are VERY worried that a recession will make it difficult for them to conduct their research and close to two-thirds indicated that their research has already been affected by the current economic recession," notes Tamara Zemlo, Ph.D., Vice President of Advisory Services. According to Zemlo, life sciences will likely fare better than other sectors of the economy, but she points out that scientists are employing a variety of ways to stretch their budgets. "Understanding how and where scientists intend to cut back will be essential for suppliers developing effective marketing and sales strategies."
To learn more about this report, a complimentary Executive Summary is available at http://www.gene2drug.com/reports/200/.
ABOUT BIOINFORMATICS, LLC
BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 42,000 biomedical researchers, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.
For more information contact: Mary Follin Manager, Marketing/Sales BioInformatics, LLC 2111 Wilson Blvd., Suite 250 Arlington, VA 22201 703.778.3080 x13 (phone) firstname.lastname@example.org http://www.gene2drug.com/
|SOURCE BioInformatics, LLC|
Copyright©2009 PR Newswire.
All rights reserved